Royal Bank Of Canada Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Key Points

• Royal Bank of Canada raised Vertex Pharmaceuticals’ price target from $576 to $600 and maintained an “outperform” rating, implying 10.8% upside. The analyst consensus is “Moderate Buy,” with an average target of $587.63.
• Vertex reported quarterly revenue of $3.44 billion, up 11.8% year over year and slightly above estimates, but earnings per share of $4.76 missed the $4.82 consensus.
• Shares fell 2.1% to $541.50, while investors weighed strong revenue growth and pipeline progress against earnings pressure from new product launches and the Crinetics acquisition.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) had its price objective upped by investment analysts at Royal Bank Of Canada from $576.00 to $600.00 in a report released on Tuesday, Benzinga reports. The firm presently has an "outperform" rating on the pharmaceutical company's stock. Royal Bank Of Canada's price objective points to a potential upside of 10.80% from the company's current price.

Other analysts have also recently issued research reports about the company. UBS Group lifted their target price on Vertex Pharmaceuticals from $585.00 to $615.00 and gave the stock a "buy" rating in a research report on Monday, September 28th. The Goldman Sachs Group set a $653.00 target price on Vertex Pharmaceuticals and gave the company a "buy" rating in a research note on Tuesday, September 1st. TD Cowen increased their price target on shares of Vertex Pharmaceuticals from $525.00 to $550.00 and gave the stock a "buy" rating in a report on Wednesday, September 23rd. Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, October 16th. Finally, Stifel Nicolaus raised their price objective on shares of Vertex Pharmaceuticals from $500.00 to $563.00 and gave the company a "hold" rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $587.63.

Vertex Pharmaceuticals Stock Down 2.1%

NASDAQ VRTX traded down $11.65 during trading hours on Tuesday, hitting $541.50. 531,346 shares of the company were exchanged, compared to its average volume of 1,385,165. Vertex Pharmaceuticals has a 52-week low of $403.16 and a 52-week high of $568.67. The firm has a market cap of $137.44 billion, a price-to-earnings ratio of 31.49, a PEG ratio of 2.54 and a beta of 0.28. The company has a 50 day moving average of $523.32 and a two-hundred day moving average of $479.96.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts' consensus estimates of $4.82 by ($0.06). The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. Vertex Pharmaceuticals's revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.80 earnings per share. On average, equities research analysts predict that Vertex Pharmaceuticals will post 16.74 EPS for the current year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. MADDEN SECURITIES Corp acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $26,000. Meeder Asset Management Inc. purchased a new position in Vertex Pharmaceuticals in the second quarter valued at about $26,000. Community Financial Services Group LLC bought a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $26,000. Elevation Wealth Partners LLC grew its position in Vertex Pharmaceuticals by 103.7% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company's stock worth $27,000 after acquiring an additional 28 shares in the last quarter. Finally, Pingora Partners LLC acquired a new position in Vertex Pharmaceuticals during the second quarter worth $32,000. Institutional investors and hedge funds own 90.96% of the company's stock.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 11.8% year over year to $3.44 billion, exceeding the $3.42 billion consensus estimate. Growth was supported by the company’s cystic fibrosis franchise and the ramp-up of newer products, including CASGEVY and JOURNAVX. Vertex Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Vertex raised its full-year 2026 revenue outlook to $13.2 billion-$13.3 billion and highlighted continued pipeline advancement and the completed acquisition of Crinetics Pharmaceuticals. Analysts also became more constructive: Cantor Fitzgerald raised its price target to $619 from $595 and maintained an “overweight” rating. Cantor Fitzgerald Vertex rating
• Neutral Sentiment: Stifel Nicolaus increased its price target to $563 from $500 but retained a “hold” rating, signaling that much of the expected upside may already be reflected in the shares. Stifel Nicolaus Vertex rating
• Negative Sentiment: Adjusted earnings of $4.76 per share fell short of estimates ranging from $4.82 to $4.92 and declined from $4.80 a year earlier. Heavy investment in new product launches and the Crinetics transaction limited profit growth despite higher sales. Vertex spends cash flow on new launches
• Negative Sentiment: The revenue outlook is only modestly above the previous forecast and roughly in line with consensus, which may disappoint investors looking for a larger guidance increase. The mixed earnings report has produced a volatile reaction, with the earnings miss and light outlook offsetting the revenue beat.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.